First investigation of MIRA-1 in multiple myeloma was conducted by Saha et al. whereby, with resemblance to PRIMA-1 treatment, MIRA-1 showed antimyeloma activity independently of p53 status [57]. Here, TP53 is linked to plasma cell myeloma.